National Depression Screening Day: Magnetic brain stimulation, psilocybin and more
In conjunction with National Depression Screening Day, Healio Psychiatry has compiled a list of most-read articles for this year related to depression research.
Magnetic brain stimulation for different forms of depression, psilocybin as an intervention for treatment-resistant depression and outcomes of esketamine nasal spray were just some of the year’s most-read stories related to depression.
New form of magnetic brain stimulation may relieve treatment-resistant depression
A new magnetic brain stimulation intervention reduced severe depression symptoms among 90% of participants in a study published in American Journal of Psychiatry. Read more.
FDA grants breakthrough designation to transcranial magnetic stimulation device for bipolar depression
The FDA granted breakthrough device designation to the NeuroStar Advanced Therapy System for the treatment of bipolar depression, according to a press release from Neuronetics Inc., the device’s manufacturer. Read more.
Safety of psilocybin lays groundwork for research in treatment-resistant depression
A psilocybin formulation was well tolerated among healthy patients, which supports research into its use for treatment-resistant depression, according to data presented at the American Society of Clinical Psychopharmacology Annual Meeting. Read more.
Data outline real-world early use of esketamine nasal spray for treatment-resistant depression
Data presented at the American Society of Clinical Psychopharmacology Annual Meeting showed prescribing practices and outcomes related to esketamine nasal spray. Read more.
Researchers find more evidence for link between depression and all-cause, CVD mortality
Individuals with depression, especially men, may be at increased risk for all-cause and CVD mortality, according to results of a prospective cohort study conducted in China and published in JAMA Network Open. Read more.